Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | Director · 10% owner | March 16, 2020 | March 16, 2020 |
| Lexeo Therapeutics, Inc.LXEO · Entity 5687 | Director | June 25, 2026 | June 29, 2026 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | May 09, 2019 | May 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date March 16, 2020 · Filed March 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Lundbeckfond Invest A/S | 1,432,722 |
Last balance in matching sequence
After 2020-03-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-03-16 · Conversion · Acquired 1,245,222 · Balance 1,245,222 F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Row 2 · 2020-03-16 · Purchase · Acquired 187,500 · Balance 1,432,722 F4: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectBy Lundbeckfond Invest A/S | 0 |
Reported balance
After 2020-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-16 · Conversion · Disposed 478,749 · Balance 0 F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Lundbeckfond Invest A/S | 0 |
Reported balance
After 2020-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-16 · Conversion · Disposed 5,470,492 · Balance 0 F2: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Lundbeckfond Invest A/S | 0 |
Reported balance
After 2020-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-16 · Conversion · Disposed 1,894,444 · Balance 0 F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2030-03-15 | Direct | 15,457 |
Reported balance
After 2020-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-03-16 · Grant · Acquired 15,457 · Balance 15,457 F5: The option vests in three equal installments on March 16, 2021, 2022 and 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F4: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.
F5: The option vests in three equal installments on March 16, 2021, 2022 and 2023.
Lexeo Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-24 | Direct | 35,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 35,000 · Balance 35,000 F1: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
Trevi Therapeutics, Inc.
Report date May 09, 2019 · Filed May 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,151,544 |
Last balance in matching sequence
After 2019-05-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-05-09 · Conversion · Acquired 776,544 · Balance 776,544 F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Row 2 · 2019-05-09 · Purchase · Acquired 375,000 · Balance 1,151,544 F2: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2019-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-09 · Conversion · Disposed 6,849,315 · Balance 0 F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,
F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:45 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001722234-26-000002 · form4-06292026_080602.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-24 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001193125-25-233531 · ownership.xml · derivative · entry 2 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001193125-25-233531 · ownership.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:00 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001415889-25-018518 · form4-06302025_050601.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-25 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 17:31 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0000950170-25-082541 · ownership.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 21:01 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0001415889-24-018343 · form4-06272024_090603.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 25, 2025, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:00 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-24-073126 · ownership.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 22:57 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002929 · doc4.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-02-01 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on November 2, 2024, and 1/48th of the shares underlying the option shall vest in equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 17,300 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-23-014861 · doc4.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 16:18 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0000899243-20-016168 · doc4.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2030-06-09 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 15,457 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008492 · doc4.xml · derivative · entry 6 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,457 Underlying: Common Stock · 15,457 shares Expires 2030-03-15 F5 · derivative.exercise_date: The option vests in three equal installments on March 16, 2021, 2022 and 2023. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries B Preferred Stock · Derivative | 1,894,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008492 · doc4.xml · derivative · entry 5 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 300,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries A Preferred Stock · Derivative | 5,470,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008492 · doc4.xml · derivative · entry 4 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 868,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionSeries Seed Preferred Stock · Derivative | 478,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008492 · doc4.xml · derivative · entry 3 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 76,003 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | PurchaseCommon Stock | 187,500 | $16.00 | $3,000,000.00 |
DisclosureSEC source: 0000899243-20-008492 · doc4.xml · nonDerivative · entry 2 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Lundbeckfond Invest A/S Disclosed balance after: 1,432,722 F4 · ownership.nature: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 16, 2020 Filed Mar 16, 2020 21:15 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | ConversionCommon Stock | 1,245,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-008492 · doc4.xml · nonDerivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Lundbeckfond Invest A/S Disclosed balance after: 1,245,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:18 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-017642 · doc4.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionSeries C Preferred Stock · Derivative | 6,849,315 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013253 · doc4.xml · derivative · entry 3 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 776,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | PurchaseCommon Stock | 375,000 | $10.00 | $3,750,000.00 |
DisclosureSEC source: 0000899243-19-013253 · doc4.xml · nonDerivative · entry 2 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,151,544 F2 · ownership.nature: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionCommon Stock | 776,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-013253 · doc4.xml · nonDerivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 776,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 07, 2019 Filed May 8, 2019 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 23,684 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-19-012648 · doc4.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,684 Underlying: Common Stock · 23,684 shares Expires 2029-05-06 F1 · derivative.exercise_date: This option was granted on May 7, 2019, effective upon the pricing of the Issuer's initial public offering. This option is scheduled to vest as to (i) 50% of the underlying shares on the earlier of (A) the first anniversary of the date of grant and (B) the date of the first annual meeting of stockholders of the Issuer held following the date of grant and (ii) the remaining 50% of the underlying shares on the earlier of (A) the second anniversary of the date of grant and (B) the date of the second annual meeting of stockholders of the Issuer held following the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 18:40 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0000899243-18-017636 · doc4.xml · derivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2028-06-19 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 19, 2019, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:22 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries B Preferred Stock · Derivative | 7,067,945 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027196 · doc4.xml · derivative · entry 4 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 984,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · ownership.nature: Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S ("LIAS"), upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:22 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries A Preferred Stock · Derivative | 11,092,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027196 · doc4.xml · derivative · entry 3 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 1,544,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · ownership.nature: Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S ("LIAS"), upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:22 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 984,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027196 · doc4.xml · nonDerivative · entry 2 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Lundbeckfond Invest A/S Disclosed balance after: 2,529,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S ("LIAS"), upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are directly held by LIAS. The Reporting Person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:22 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 1,544,858 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027196 · doc4.xml · nonDerivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Lundbeckfond Invest A/S Disclosed balance after: 1,544,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Lundbeckfond Invest A/S ("LIAS"), upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are directly held by LIAS. The Reporting Person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 21, 2017 Filed Feb 13, 2018 17:38 UTC Amendment | scPharmaceuticals Inc. SCPH · Entity 74456 | PurchaseCommon Stock | 654,762 | $14.00 | $9,166,668.00 |
DisclosureSEC source: 0000899243-18-003707 · doc4a.xml · nonDerivative · entry 1 Agger Mette Kirstine · CIK 0001722234 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By: Lundbeckfond Invest A/S Disclosed balance after: 3,183,986 F1 · shares: On November 21, 2017, the Reporting Person filed a Form 4 which inadvertently excluded the purchase of shares in the Initial Public Offering of the Issuer by Lundbeckfond Invest A/S ("LIAS") of 654,762 shares of Common Stock (the "Purchase"). This amendment corrects the exclusion of the purchase by LIAS. The Purchase was reported on a Form 4 filed by LIAS with the U.S. Securities and Exchange Commission on November 21, 2017. F2 · ownership.nature: These shares are directly held by LIAS. The Reporting Person is the Managing Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.